A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is application/pdf
.
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial
2016
Atherosclerosis
Background and aims: To assess the efficacy and safety of K-877 (Pemafibrate), a novel selective peroxisome proliferator-activated receptor a modulator (SPPARMa) that possesses unique PPARa activity and selectivity, compared with placebo and fenofibrate in dyslipidaemic patients with high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) levels. Methods and results: This study was a double blind, placebo-controlled, parallel-group 12-week clinical trial. The study
doi:10.1016/j.atherosclerosis.2016.02.029
pmid:27062408
fatcat:jstsen5tfjaylczwifeqouapoy